Use of cookies by
Norton Rose Fulbright
We use cookies to deliver our online services. Details and instructions on how to disable those cookies are set out at By continuing to use this website you agree to our use of our cookies unless you have disabled them.

Paul Keller


Paul Keller

New York

T:+1 212 318 3212

With nearly two decades of experience, Paul's practice focuses on patent litigation and trade secret litigation. He has represented a wide range of clients in all stages of lawsuits from pre-suit investigations to final disposition of jury and bench trials, including the presentation of arguments at Markman, discovery-dispute hearings, and direct and cross examination of witnesses. 

Paul's most recent litigation experiences include:

  • Acting as US counsel in a historic US/Canadian cross-border action representing the Canadian Monitor and Canadian estates in a dispute over the allocation of $7.3 billion in liquidation proceeds stemming primary from the sale of the debtors' massive patent portfolio;
  • Pursuing US civil misappropriation of trade secret claims against three Chinese nationals on behalf of a large chipset component manufacturer with a companion matter in the Chinese court; and 
  • The first jury verdict of non-infringement and invalidity in the Eastern District of Texas.

Paul's work has spanned a variety of industries and technologies, including supply chain management systems, global positioning systems, electronic check processing, compression/decompression software, financial analysis software, electronic futures exchanges, simulation manufacturing modeling, on-line gift registries, digital cameras, semiconductor wafer manufacturing, game controllers, medical devices, and gypsum wall boards.

Paul also has represented a number of clients in ANDA litigation and other biologic patent litigation, including matters involving recombinant interferon-ß and recombinant erythropoietin and gene activation technology.

In addition to his litigation work, Paul has expertise in transactional IP issues, such as advising clients regarding the licensing of their intellectual property and active involvement in due diligence investigations and counseling in numerous acquisitions, potential acquisitions, and other investments.
Paul's pro bono work has included the successful representation of a group of disabled persons against one of the largest drug store chains in the country for violations of the Americans With Disabilities Act.
[+Open all]
  • Education


    JD, with honors, Yeshiva University, Benjamin N. Cardozo School of Law, 1997
    BA, Economics, Fordham University, 1994


  • Representative experience

    Paul's representative matters include those involving:

    • radio frequency chip design
    • driver safety assistance systems 
    • toy manufacturing and design 
    • push/pull email exchange 
    • signal processing 
    • electronic check processing 
    • compression/decompression technology 
    • arthroscopic medical devices 
    • electronic futures exchanges 
    • image processing 
    • global positioning systems 
    • game controllers
  • Admissions
    • New York State Bar License
  • Rankings and recognitions
    • New York Metro Super Lawyers, intellectual property litigation, Thomson Reuters, 2012 - 2017
    • Legal 500 US, recommended lawyer, International litigation; Intellectual property - Patent litigation - full coverage, The Legal 500, 2016
  • Publications
    • Co-author, "A Few Things To Consider Before Patenting Blockchain Tech," Law360, Sept. 27, 2016
    • Co-author, "What You Should Know About Trade Secret Law In Saudi Arabia," Law360, April 26, 2016
    • Author, "Patent litigants beware: awards of attorneys' fees just got easier with Federal Circuit's Kilopass decision," Journal of Intellectual
    • Author, "Property Law and Practice," March 27, 2014
    • Author, "Federal Circuit Limits Equivalence Doctrine," NY Law Journal, May 7, 2001
    • Author, "US Court Strips Authors of Online Rights," IP Worldwide, Jan/Feb 1998
    • Co-author, "Getting US Trade Secret Evidence Into Chinese Courts," Law360, February 23, 2016